Loading…
Reported covered position: Snr Cnsl, Joint Econ Committee, Mar 17-Nov 17; Leg cnsl, Sen Heinrich, Apr 14-Mar 17; Leg Asst, Rep Doris Matsui, Dec 11-Apr 14; Leg Asst, Senate Judiciary Committee, May 09-Aug 09; Research Analyst, Senate Small Business Committee, Jun 07-Aug 08
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
SUPPORT for Patients and Communities Reauthorization Act of 2023
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to Substance Use Disorder programs; S. 2433 - SUPPORT for Patients and Communities Reauthorization Act of 2023 funding; Issues related to behavioral health.
Issues related to fentanyl: Bruce's Law (H.R. 9221 / S. 4358, 117th Congress); and incentives for state participation in existing national data reporting tools to inform overdose prevention efforts and target naloxone distribution.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
1-800 CONTACTS via AKIN GUMP STRAUSS HAUER & FELD
2023 · third_quarter · Q3
Legislation related to the Federal Trade Commission Contact Lens Rule.
Legislation related to the Federal Trade Commission Contact Lens Rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| HILL-ROM |
| 10 |
| 2018–2020 |
| CENTRIENT PHARMACEUTICALS LLC | 9 | 2021–2023 |
| GILEAD SCIENCES, INC. | 9 | 2019–2023 |
| LABORATORY CORPORATION OF AMERICA HOLDINGS | 9 | 2020–2022 |
| COALITION TO HEAL INVISIBLE WOUNDS | 8 | 2018–2020 |
| SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) | 8 | 2021–2023 |
| 1-800 CONTACTS | 7 | 2021–2023 |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | 2021–2023 |
| BARLOW RESPIRATORY HOSPITAL | 6 | 2022–2023 |
| ResMed Corp. | 6 | 2019–2020 |
| US PHYSICIAN PARTNERS (INFORMAL COALITION) | 6 | 2019–2020 |
| AKEBIA THERAPEUTICS, INC. | 5 | 2020–2021 |
| CORDANT HEALTH SOLUTIONS | 5 | 2018–2019 |
| DJI TECHNOLOGY, INC. | 5 | 2019–2020 |
| OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC. | 5 | 2018–2019 |
| SYRACUSE UNIVERSITY | 5 | 2019 |
| BARRY THAGGARD MAY & BAILEY, LLP | 4 | 2020 |
| CHARLOTTE'S WEB, INC. | 4 | 2019–2020 |
| Global Healthcare Exchange, LLC | 4 | 2020 |
| HEALTHCARE LEADERSHIP COUNCIL | 4 | 2020–2021 |
| RESTAURANT BRANDS INTERNATIONAL INC (RBI) | 4 | 2020 |
| SEPSIS STAKEHOLDER COALITION | 4 | 2019 |
| TWENTY HOLDINGS INC | 4 | 2021 |
| WCNSM ENTERPRISE, LLX | 4 | 2022–2023 |
| AMERICAN COLLEGE OF GASTROENTEROLOGY | 3 | 2020–2021 |
| AON SERVICE CORPORATION | 3 | 2021 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 3 | 2018–2019 |
| CONSUMER SAFETY TECHNOLOGY, LLC DBA INTOXALOCK | 3 | 2019–2020 |
| DTHERA SCIENCES, INC. | 3 | 2019 |
| MCKESSON CORPORATION | 3 | 2021–2022 |
| MICRON TECHNOLOGY, INC. | 3 | 2021–2022 |
| SOCIETY TO IMPROVE DIAGNOSIS IN MEDICINE | 3 | 2020 |
| STOPIT SOLUTIONS | 3 | 2021 |
| TERRASCALE | 3 | 2022 |
| ZP BETTER TOGETHER, LLC | 3 | 2020 |
| ZTE CORPORATION | 3 | 2021–2022 |
| BOOZ ALLEN HAMILTON INC. | 2 | 2022 |
| CRUISE LINES INTERNATIONAL ASSOCIATION | 2 | 2020 |
| GOJO INDUSTRIES | 2 | 2021 |
| MANAGEMENT RESEARCH SERVICES, INC. | 2 | 2020 |
| MINOR LEAGUE BASEBALL RELIEF, INC | 2 | 2021 |
| NATIONAL IMMIGRATION LAW CENTER | 2 | 2021 |
| ABIOMED, INC. | 1 | 2022 |
| ACCENTURE LLP | 1 | 2020 |
| BRADLEY LANE INVESTMENT COMPANY | 1 | 2022 |
| MAINSTAY MEDICAL, LTD. | 1 | 2022 |
| MIDDLEGROUND CAPITAL | 1 | 2020 |
| SENSEONICS INCORPORATED | 1 | 2019 |
| SURGERY PARTNERS | 1 | 2021 |
| St. Thomas University | 1 | 2020 |
| UNIVERSITY OF HOUSTON | 1 | 2018 |
Issues related to Substance Use Disorder programs; S.3476 - SUPPORT Act of 2022 funding; Issues related to behavioral health.
Issues related to fentanyl: Bruce's Law (H.R. 9221 / S. 4358, 117th Congress); and incentives for state participation in existing national data reporting tools to inform overdose prevention efforts and target naloxone distribution.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Synthetic Opioid Danger Awareness Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Synthetic Opioid Danger Awareness Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Synthetic Opioid Danger Awareness Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Synthetic Opioid Danger Awareness Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 4479, the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021; issues related to radiation therapy reimbursement and alternative payment models; issues related to telehealth; issues related to COVID-19 testing; H.R. 4479/S. 2609 - the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021.
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 4479/S. 2609 - the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021; issues re: radiation therapy reimbursement and alternative payment models; issues re: telehealth; issues re: COVID-19 testing.
Collaborate in an Orderly and Cohesive Manner Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Collaborate in an Orderly and Cohesive Manner Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Collaborate in an Orderly and Cohesive Manner Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Collaborate in an Orderly and Cohesive Manner Act
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Pharmacy and Medically Underserved Areas Enhancement Act
Client: MCKESSON CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 4479, the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021; issues related to radiation therapy reimbursement and alternative payment models; issues related to telehealth; issues related to COVID-19 testing; H.R. 4479/S. 2609 - the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021.
Facilitating Innovative Nuclear Diagnostics Act of 2021
Client: SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) · Firm: AKIN GUMP STRAUSS HAUER & FELD
H.R. 4479/S. 2609 - the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021; issues re: radiation therapy reimbursement and alternative payment models; issues re: telehealth; issues re: COVID-19 testing.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Comprehensive Addiction Resources Emergency Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Strengthening the Public Health Workforce Act
Client: GILEAD SCIENCES INC · Firm: AKIN GUMP STRAUSS HAUER & FELD
International trade and protection of intellectual property, HIV policy issue, Hepatitis C (HCV) policy issues, the CREATES Act (S.3506); PEPFAR; public health initiatives around opioids and infectious diseases.; general healthcare issues.
Strengthening the Public Health Workforce Act
Client: GILEAD SCIENCES INC · Firm: AKIN GUMP STRAUSS HAUER & FELD
International trade and protection of intellectual property, HIV policy issue, Hepatitis C (HCV) policy issues, the CREATES Act (S.3506); PEPFAR; public health initiatives around opioids and infectious diseases.; general healthcare issues.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Advocacy regarding solutions to preserve access to emergency air ambulance services, particularly in rural areas, including implementation of the Consolidated Appropriations Act, 2021 (including the No Surprises Act), (H.R. 133 116th Cong.); support for air ambulance cost and claims data reporting program and Medicare reimbursement; support for emergency first responder COVID-19 relief and funding through the Provider Relief Fund.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; H.R. 1384/S. 445 - Mainstreaming Addiction Treatment Act; H.R. 2067/S. 2235 - Medication Access and Training Expansion Act; Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067).
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; H.R. 1384/S. 445 - Mainstreaming Addiction Treatment Act; H.R. 2067/S. 2235 - Medication Access and Training Expansion Act; Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Eliminating the Provider Relief Fund Tax Penalties Act of 2021
Client: AIR EVAC LIFETEAM · Firm: AKIN GUMP STRAUSS HAUER & FELD
Air Ambulance and Patient Billing Advisory Committee, and implementation of the No Surprises Act, as included in the Consolidated Appropriations Act, 2021 (P.L. 116-260); eliminating the Provider Relief Fund Tax Penalties Act of 2021 (H.R. 2079)
Eliminating the Provider Relief Fund Tax Penalties Act of 2021
Client: AIR EVAC LIFETEAM · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of the No Surprises Act, as included in the Consolidated Appropriations Act, 2021 (P.L. 116-260); eliminating the Provider Relief Fund Tax Penalties Act of 2021 (H.R. 2079).
Elijah E. Cummings Lower Drug Costs Now Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Center for Medicare & Medicaid Innovation, HR 3 and other drug pricing proposals.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Center for Medicare & Medicaid Innovation, H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act and other drug pricing proposals.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: AKIN GUMP STRAUSS HAUER & FELD
Center for Medicare & Medicaid Innovation, H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act and other drug pricing proposals.
Minor League Baseball Relief Act
Client: MINOR LEAGUE BASEBALL RELIEF, INC · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to the Minor League Baseball COVID Relief Act, H.R. 4150 and S. 2233.
Minor League Baseball Relief Act
Client: MINOR LEAGUE BASEBALL RELIEF, INC · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to the Minor League Baseball COVID Relief Act, H.R. 4150 and S. 2233.
IRS PRIORITIES Act of 2022
Client: MCKESSON CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748 - CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution.
Pharmacy and Medically Underserved Areas Enhancement Act
Client: MCKESSON CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act
Pharmacy and Medically Underserved Areas Enhancement Act
Client: MCKESSON CORPORATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to COVID medical response; COVID-19 vaccine distribution; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act.
Minor League Baseball Relief Act
Client: MINOR LEAGUE BASEBALL RELIEF, INC · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to the Minor League Baseball COVID Relief Act, H.R. 4150 and S. 2233.
Minor League Baseball Relief Act
Client: MINOR LEAGUE BASEBALL RELIEF, INC · Firm: AKIN GUMP STRAUSS HAUER & FELD
Issues related to the Minor League Baseball COVID Relief Act, H.R. 4150 and S. 2233.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; H.R. 1384/S. 445 - Mainstreaming Addiction Treatment Act; H.R. 2067/S. 2235 - Medication Access and Training Expansion Act; Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; H.R. 1384/S. 445 - Mainstreaming Addiction Treatment Act; H.R. 2067/S. 2235 - Medication Access and Training Expansion Act; Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067).
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Mainstreaming Addiction Treatment Act of 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Opioids/substance use; laboratories; Comprehensive Addiction and Recovery Act (CARA) 3.0 (S.987)
Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748 - CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution.
Consolidated Appropriations Act, 2021
Client: AMERICAN MEDICAL REHABILITATION PROVIDERS ASSOCIATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
Unified post-acute care payment systems; IRF payment and coverage; Medicare Advantage and Prior Authorization; Regulatory relief and reform issues; Issues related to continuing care hospitals.; COVID-19 issues COVID-19 health care legislative and regulatory implementation and funding issues, including IRFs, Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), the CARES Act (S. 3548/H.R. 748), The Heroes Act (H.R. 6800), Consolidated Appropriations Act, 2021 (H.R. 133)
Consolidated Appropriations Act, 2021
Client: BARRY THAGGARD MAY & BAILEY, LLP · Firm: AKIN GUMP STRAUSS HAUER & FELD
COVID-19 issues related to COVID-19 health care legislative and regulatory implementation and funding issues; COVID-19 relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), the CARES Act (S. 3548/H.R. 748); implementation of Provider Relief Funding and other COVID-19 relief, including Medicare/Medicaid waivers; and the HEROES Act (H.R. 6800); Delivering Immediate Relief to America's Families, Schools and Small Businesses Act (S. 4775), and Health, Economic Assistance, Liability Protection and Schools (HEALS) Act; Continuing Appropriations Act, 2021 and Other Extensions Act (H.R.8337); Consolidated Appropriations Act, 2021 (H.R. 133); telehealth, rural health; The Resetting The Impact Act (TRIA)(H.R. 8826) and Critical Access Hospitals.
Consolidated Appropriations Act, 2021
Client: HILL-ROM · Firm: AKIN GUMP STRAUSS HAUER & FELD
Technology research; Telemedicine and connected care; Remote patient monitoring; Implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); The implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); Diabetic retinopathy; safe patient handling, FDA reform; Sepsis funding and education; Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R.5254).; COVID-19 health care legislative and regulatory implementation and funding issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), the CARES Act (S. 3548/H.R. 748) and the HEROES Act (H.R. 6800), Consolidated Appropriations Act, 2021 (H.R. 133)
Consolidated Appropriations Act, 2021
Client: AIR EVAC LIFETEAM · Firm: AKIN GUMP STRAUSS HAUER & FELD
Advocacy regarding solutions to address balance billing and preserve access to emergency air ambulance services, particularly in rural areas, including the Consolidated Appropriations Act, 2021 (H.R. 133), Lower Health Care Costs Act (S. 1895), No Surprises Act (H.R. 3630), Ban Surprise Billing Act (H.R. 5800), Consumer Protections Against Surprise Medical Bills Act of 2020 (H.R. 5826), the Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074), and CARES Act (H.R. 748); Paycheck Protection Program and Health Care Enhancement Act (H.R. 266); support for air ambulance cost and claims data reporting program; support for emergency first responder COVID-19 relief.
Consolidated Appropriations Act, 2021
Client: SHATTERPROOF · Firm: AKIN GUMP STRAUSS HAUER & FELD
Implementation of and funding for SUPPORT Act legislation related to addressing the opioid crisis and additional addiction issues, including H.R. 2482/S. 2074, H.R. 3734/S. 1448, and S. 1012/H.R. 2062 education re Shatterproof's Addiction Treatment Locator, Analysis, and Standards (ATLAS) tool addiction prevention and assistance efforts in the workplace and advise client regarding federal legislative and regulatory response to the COVID-19 Cares Act and other federal initiatives as they relate to the quality of, and access to substance use disorder treatment. Implementation of and funding for SUPPORT for Patients and Communities Act (P.L. 115-271) legislation related to addressing the opioid crisis and additional addiction issues, including the Mainstreaming Addiction Treatment Act (H.R. 2482/S. 2074) Medication Access and Training Expansion Act (H.R. 2482); PDMPs Help Patients Act of 2019 (H.R. 3927); Consolidated Appropriations Act, 2021 (H.R. 133).
Consolidated Appropriations Act, 2021
Client: SOCIETY TO IMPROVE DIAGNOSIS IN MEDICINE · Firm: AKIN GUMP STRAUSS HAUER & FELD
Promote policy agenda to improve medical and clinical errors; FY 2021 appropriations; COVID-19 response; HEROES Act (H.R. 6800); Improving Diagnosis in Medicine Act (H.R. 5014).; the Health, Economic Assistance, Liability Protection and Schools (HEALS) Act; FY 2021 Consolidated Appropriations Act (H.R. 133).
Consolidated Appropriations Act, 2021
Client: GLOBAL HEALTHCARE EXCHANGE, LLC · Firm: AKIN GUMP STRAUSS HAUER & FELD
COVID-19 pandemic response; issues related to the health care supply chain; Medical Supplies for Pandemics Act (H.R. 6531); Implementation of CARES Act (P.L. 116-136); Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act (H.R. 6800); Health, Economic Assistance, Liability Protection and Schools (HEALS) Act; Strengthening America's Strategic National Stockpile Act (H.R. 7574); Make PPE in America Act (S. 4578/H.R. 8324); FY 2021 National Defense Authorization Act (H.R. 6395); CASH Act of 2020 (H.R. 9051); FY 2021 Consolidated Appropriations Act (H.R. 133).
Consolidated Appropriations Act, 2021
Client: BARRY THAGGARD MAY & BAILEY, LLP · Firm: AKIN GUMP STRAUSS HAUER & FELD
COVID-19 issues related to COVID-19 health care legislative and regulatory implementation and funding issues; COVID-19 relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), the CARES Act (S. 3548/H.R. 748); implementation of Provider Relief Funding and other COVID-19 relief, including Medicare/Medicaid waivers; and the HEROES Act (H.R. 6800); Delivering Immediate Relief to America's Families, Schools and Small Businesses Act (S. 4775), and Health, Economic Assistance, Liability Protection and Schools (HEALS) Act; Continuing Appropriations Act, 2021 and Other Extensions Act (H.R.8337); Consolidated Appropriations Act, 2021 (H.R. 133); telehealth, rural health, ; The Resetting The Impact Act (TRIA)(H.R. 8826); and Critical Access Hospitals.
Consolidated Appropriations Act, 2021
Client: HILL-ROM · Firm: AKIN GUMP STRAUSS HAUER & FELD
Technology research; Telemedicine and connected care; Remote patient monitoring; Implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); The implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); Diabetic retinopathy; safe patient handling, FDA reform; Sepsis funding and education; Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R.5254).; COVID-19 health care legislative and regulatory implementation and funding issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), the CARES Act (S. 3548/H.R. 748) and the HEROES Act (H.R. 6800), Consolidated Appropriations Act, 2021 (H.R. 133)
Consolidated Appropriations Act, 2021
Client: AMERICAN MEDICAL REHABILITATION PROVIDERS ASSOCIATION · Firm: AKIN GUMP STRAUSS HAUER & FELD
COVID-19 issues related to COVID-19 health care legislative and regulatory implementation and funding issues, including inpatient rehab hospitals (IRFs), Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), and the CARES Act (S. 3548/H.R. 748), Consolidated Appropriations Act, 2021 (H.R. 133).; Unified post-acute care payment system; Medicare Advantage and Prior Authorization including H.R.3107; Site neutral payment issues; Medical necessity to post-acute care reform; The Preserving rehabilitation Innovation Centers Act of 2019 (S.594, H.R. 1901); Implementation of IMPACT Act of 2014 (P.L. 113-185); Implementation of H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015; Comprehensive Care for Joint Replacement(CCJR) Model; Medicare Advantage and managed care related issues; Value based purchasing issues, Recovery Audit Contractor issues, prior authorization, PPS excluded hospitals operation of excluded units, 3-hour rule, 60% rule, LTCH exempt unit issue; Preserving Rehabilitation Innovation Centers Act (H.R.1901/S.594); Improving Seniors Timely Access to Care Act (H.R.3107); The BETTER Act (H.R.3417); The Resetting The Impact Act (TRIA) (H.R. 8826); Implementation of the Continuing Care Hospital.
Further Consolidated Appropriations Act, 2020
Client: HILL-ROM · Firm: AKIN GUMP STRAUSS HAUER & FELD
COVID-19 health care issues, including ventilators, device and supply chain issues, hospitals and other relief funding within the Families First Coronavirus Response Act (H.R. 6201), Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074), and the CARES Act (S. 3548/H.R. 748); Technology research; Telemedicine and connected care; Remote patient monitoring; Implementation of Patient Protection and Affordable Care Act (H.R. 3590/P.L. 111-148); Health Care and Education Reconciliation Act (H.R. 4872/P.L. 111-152); The implementation of The Medicare Access and CHIP re authorization Act (H.R. 2); Diabetic retinopathy; safe patient handling, FDA reform; Sepsis funding and education; Further Consolidated Appropriations Act, 2020, (H.R.1865); Diabetic Vision Loss and Blindness Prevention Act of 2019 (H.R.5254).
2023 · third_quarter · Q3
Fiscal Year 2024 appropriations for dangers of fentanyl awareness campaign, the Practitioner Education Grant Program, and Customs and Border Protection.
Issues related to Substance Use Disorder programs; S. 2433 - SUPPORT for Patients and Communities Reauthorization Act of 2023 funding; Issues related to behavioral health.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES INC via AKIN GUMP STRAUSS HAUER & FELD
2023 · third_quarter · Q3
General healthcare issues; pandemic related issues; drug pricing issues; PBM reform.
Filing targets: SENATE, White House Office
CENTRIENT PHARMACEUTICALS LLC via AKIN GUMP STRAUSS HAUER & FELD
2023 · third_quarter · Q3
Issues related to onshoring supply chains and biomanufacturing of essential medicines to the United States.
Issues related to onshoring supply chains and biomanufacturing of essential medicines to the United States.
Issues related to onshoring supply chains and biomanufacturing of essential medicines to the United States.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Science & Technology Policy (OSTP), SENATE, White House Office
BARLOW RESPIRATORY HOSPITAL via AKIN GUMP STRAUSS HAUER & FELD
2023 · second_quarter · Q2
Issues related to an enforcement action under the Long-Term Care Hospital Quality Reporting Program.
Issues related to an enforcement action under the Long-Term Care Hospital Quality Reporting Program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS)
WCNSM ENTERPRISE, LLX via AKIN GUMP STRAUSS HAUER & FELD
2023 · second_quarter · 2T
Pursue federal funding opportunities for air purification and disinfection systems.
Pursue federal funding opportunities for air purification and disinfection systems.
Pursue federal funding opportunities for air purification and disinfection systems.
Pursue federal funding opportunities for air purification and disinfection systems.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via AKIN GUMP STRAUSS HAUER & FELD
2023 · second_quarter · Q2
Issues relating to drug pricing proposals including the Inflation Reduction Act (PL 117-169). Rx oversight issues. PAHPA reauthorization and drug pricing issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2023 · second_quarter · Q2
Issues regarding access to cancer care and treatment; issues related to medical device remanufacturing.
Issues related to cancer care and treatment, medical device remanufacturing, and health care workforce.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2023 · second_quarter · Q2
Issues related to Substance Use Disorder programs; S.3476 - SUPPORT Act of 2022 funding; Issues related to behavioral health.
Fiscal Year 2024 appropriations for dangers of fentanyl awareness campaign and Customs and Border Protection.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2023 · first_quarter · Q1
Issues related to fentanyl: Bruce's Law (H.R. 9221 / S. 4358, 117th Congress); and incentives for state participation in existing national data reporting tools to inform overdose prevention efforts and target naloxone distribution.
Fiscal Year 2024 appropriations for dangers of fentanyl awareness campaign, the Practitioner Education Grant Program, and Customs and Border Protection.
Issues related to fentanyl: conditioning foreign aid; implementation of the Fentanyl Sanctions Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTRIENT PHARMACEUTICALS LLC via AKIN GUMP STRAUSS HAUER & FELD
2023 · first_quarter · Q1
Issues related to onshoring supply chains and manufacturing of essential medicines to the United States.
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), SENATE, White House Office
WCNSM ENTERPRISE, LLX via AKIN GUMP STRAUSS HAUER & FELD
2023 · first_quarter · Q1
Pursue federal funding opportunities for air purification and disinfection systems.
Pursue federal funding opportunities for air purification and disinfection systems.
Pursue federal funding opportunities for air purification and disinfection systems.
CVS HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2023 · first_quarter · 1T
Strategic and policy advice on general healthcare issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBOTT LABORATORIES via AKIN GUMP STRAUSS HAUER & FELD
2023 · first_quarter · Q1
Strategic and policy advice related to general healthcare issues, including COVID-19 legislation and regulations; issues related to infant formula; monitor telehealth developments, appropriations, and other issues related to healthcare diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TERRASCALE via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · 4T
Issues pertaining to green energy initiatives.
Issues pertaining to green energy initiatives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTRIENT PHARMACEUTICALS LLC via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · 4A
Issues related to onshoring supply chains and manufacturing of essential medicines to the United States.
Issues related to onshoring supply chains and manufacturing of essential medicines to the United States.
Issues related to onshoring supply chains and manufacturing of essential medicines to the United States.
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, White House Office
CENTRIENT PHARMACEUTICALS LLC via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Issues related to onshoring supply chains and manufacturing of essential medicines to the United States.
Issues related to onshoring supply chains and manufacturing of essential medicines to the United States.
Issues related to onshoring supply chains and manufacturing of essential medicines to the United States.
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, White House Office
ZTE CORPORATION via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Discussions concerning the report required by Section 1260J of the National Defense Authorization Act for Fiscal Year 2020 (Pub L. 116-92) and brief officials on ZTE compliance with applicable U.S. law.
Discussions concerning the report required by Section 1260J of the National Defense Authorization Act for Fiscal Year 2020 (Pub L. 116-92) and brief officials on ZTE compliance with applicable U.S. law.
Discussions concerning the report required by Section 1260J of the National Defense Authorization Act for Fiscal Year 2020 (Pub L. 116-92) and brief officials on ZTE compliance with applicable U.S. law.
TERRASCALE via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Issues pertaining to green energy initiatives.
Issues pertaining to green energy initiatives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CVS HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Strategic and policy advice on general health care issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BARLOW RESPIRATORY HOSPITAL via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Issues related to an enforcement action under the Long Term Care Hospital Quality Reporting Program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ABBOTT LABORATORIES via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Strategic and policy advice related to healthcare issues, including COVID-19 legislation and regulations; monitor telehealth developments, appropriations, and other issues related to healthcare diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
1-800 CONTACTS via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Legislation related to the Federal Trade Commission Contact Lens Rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Issues relating to drug pricing proposals including the Inflation Reduction Act. Policy riders related to reauthorization of FDA user fee agreements; Consolidated Appropriations Act, 2023 (P.L. 117-328).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
General issues regarding access to cancer care and treatment; issues regarding medical device remanufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WCNSM ENTERPRISE, LLX via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Pursue federal funding opportunities for air purification and disinfection systems.
Pursue federal funding opportunities for air purification and disinfection systems.
Pursue federal funding opportunities for air purification and disinfection systems.
LABORATORY CORPORATION OF AMERICA HOLDINGS via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Nonhuman primate supply chain issues/China export ban; issues relating to use of plastic blood tubes.
Filing targets: Occupational Safety & Health Administration (OSHA)
GILEAD SCIENCES INC via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
International trade and protection of intellectual property, HIV policy issue, Hepatitis C (HCV) policy issues, the CREATES Act (S.3506); PEPFAR; public health initiatives around opioids and infectious diseases.; general healthcare issues.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), SENATE, U.S. Trade Representative (USTR)
BOOZ ALLEN HAMILTON INC. via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · Q4
Issues related to electronic health record modernization, National Defense Authorization Act, and artificial intelligence.
Issues related to electronic health record modernization, National Defense Authorization Act, and artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TERRASCALE via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · RR
Provide advice and policy counsel on political/regulatory challenges in U.S. and non-U.S. markets green energy markets.
Provide advice and policy counsel on political/regulatory challenges in U.S. and non-U.S. markets green energy markets.
Provide advice and policy counsel on political/regulatory challenges in U.S. and non-U.S. markets green energy markets.
WCNSM ENTERPRISE, LLX via AKIN GUMP STRAUSS HAUER & FELD
2022 · fourth_quarter · RR
Identify and pursue federal funding of new air purification and disinfection systems.
Identify and pursue federal funding of new air purification and disinfection systems.
Identify and pursue federal funding of new air purification and disinfection systems.
ABBOTT LABORATORIES via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · 2A
Strategic and policy advice related to health care issues, including COVID-19 legislation and regulations; monitor telehealth developments, appropriations, and other issues related to health care diagnostics; outreach and advocacy for future pandemic preparedness.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
FDA user fee authorization, issues relating to drug pricing proposals including the Inflation Reduction Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
CVS HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
Strategic and policy advice on general health care issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BARLOW RESPIRATORY HOSPITAL via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
Issues related to an enforcement action under the Long Term Care Hospital Quality Reporting Program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ABBOTT LABORATORIES via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
Strategic and policy advice related to healthcare issues, including COVID-19 legislation and regulations; monitor telehealth developments, appropriations, and other issues related to healthcare diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LABORATORY CORPORATION OF AMERICA HOLDINGS via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
Nonhuman primate supply chain issues/China export ban; issues relating to use of plastic blood tubes.
Filing targets: Occupational Safety & Health Administration (OSHA)
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES INC via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
International trade and protection of intellectual property, HIV policy issue, Hepatitis C (HCV) policy issues, the CREATES Act (S.3506); PEPFAR; public health initiatives around opioids and infectious diseases.; general healthcare issues.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
Issues re: access to cancer care and treatment; issues re: medical device remanufacturing
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ZTE CORPORATION via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
Discussions concerning the report required by Section 1260J of the National Defense Authorization Act for Fiscal Year 2020 (Pub L. 116-92) and brief officials on ZTE compliance with applicable U.S. law.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTRIENT PHARMACEUTICALS LLC via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · Q3
Issues regarding solutions for onshoring supply chain and manufacturing of essential medicines in the United States.
Advocacy regarding solutions for onshoring supply chain and manufacturing of essential medicines in the United States.; Issues related to health care supply chain and Mexico regulatory delays.
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
BOOZ ALLEN HAMILTON INC. via AKIN GUMP STRAUSS HAUER & FELD
2022 · third_quarter · RR
Artificial intelligence; electronic health record modernization; cybersecurity; FY23 National Defense Authorization Act
Artificial intelligence; electronic health record modernization; cybersecurity; FY23 National Defense Authorization Act
Artificial intelligence; electronic health record modernization; cybersecurity; FY23 National Defense Authorization Act
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · Q2
FDA user fee authorization, issues relating to drug pricing proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENTRIENT PHARMACEUTICALS LLC via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · Q2
Advocacy regarding solutions for onshoring supply chain and manufacturing of essential medicines back to the United States.; Issues related to health care supply chain and Mexico regulatory delays.
Advocacy regarding solutions for onshoring supply chain and manufacturing of essential medicines back to the United States.
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
CVS HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · Q2
Strategic and policy advice on general health care issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BARLOW RESPIRATORY HOSPITAL via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · Q2
Issues related to an enforcement action under the Long Term Care Hospital Quality Reporting Program.
Issues related to an enforcement action under the Long Term Care Hospital Quality Reporting Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBOTT LABORATORIES via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · Q2
Strategic and policy advice related to health care issues, including COVID-19 legislation and regulations; monitor telehealth developments, appropriations, and other issues related to health care diagnostics; outreach and advocacy for future pandemic preparedness.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
1-800 CONTACTS via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · Q2
Legislation related to the Federal Trade Commission Contact Lens Rule.
Legislation related to the Federal Trade Commission Contact Lens Rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · Q2
H.R. 4479/S. 2609 - the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021; issues re: radiation therapy reimbursement and alternative payment models; issues re: telehealth; issues re: COVID-19 testing.
General issues regarding access to cancer care and treatment; issues re: right to repair proposals; issues re: medical device remanufacturing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
LABORATORY CORPORATION OF AMERICA HOLDINGS via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · Q2
Nonhuman primate supply chain issues/China export ban; issues relating to use of plastic blood tubes.
Filing targets: Occupational Safety & Health Administration (OSHA)
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · Q2
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABIOMED, INC. via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · Q2
FDA user fee reauthorization and the use of real world data.
Filing targets: SENATE
BRADLEY LANE INVESTMENT COMPANY via AKIN GUMP STRAUSS HAUER & FELD
2022 · second_quarter · RR
Location of ARPA-H.
Location of ARPA-H.
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
H.R. 4479, the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021; issues related to radiation therapy reimbursement and alternative payment models; issues related to telehealth; issues related to COVID-19 testing; H.R. 4479/S. 2609 - the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021.
General issues regarding access to cancer care and treatment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
1-800 CONTACTS via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
Legislation related to the Federal Trade Commission Contact Lens Rule.
Legislation related to the Federal Trade Commission Contact Lens Rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment; Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LABORATORY CORPORATION OF AMERICA HOLDINGS via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
Nonhuman primate supply chain issues/China export ban; issues relating to use of plastic blood tubes.
Filing targets: Occupational Safety & Health Administration (OSHA)
CENTRIENT PHARMACEUTICALS LLC via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
Advocacy regarding solutions for onshoring supply chain and manufacturing of critical medicines back to the United States.; Issues related to health care supply chain and Mexico regulatory delays.
Advocacy regarding solutions for onshoring supply chain and manufacturing of critical medicines back to the United States.
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
AIR EVAC LIFETEAM via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
Implementation of the No Surprises Act, as included in the Consolidated Appropriations Act, 2021 (P.L. 116-260); Build Back Better Act health care workforce provisions, Pathway to Health Careers and National Health Services Corps.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Treasury, Dept of
BARLOW RESPIRATORY HOSPITAL via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
Issues related to an enforcement action under the Long Term Care Hospital Quality Reporting Program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MICRON TECHNOLOGY, INC. via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
Strategic and policy advice related to investment tax credits for semiconductors.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
CVS HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
Strategic and policy advice on general health care issues, including Medicare Advantage, Medicaid redeterminations, and the unwinding of the public health emergency.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ABBOTT LABORATORIES via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
Strategic and policy advice related to health care issues, including COVID-19 legislation and regulations; monitor telehealth developments, appropriations, and other issues related to health care diagnostics; outreach and advocacy for future pandemic preparedness.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE
MCKESSON CORPORATION via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · Q1
Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MAINSTAY MEDICAL, LTD. via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · RR
Advocacy related to non-opioid pain management devices.
Advocacy related to non-opioid pain management devices.
BARLOW RESPIRATORY HOSPITAL via AKIN GUMP STRAUSS HAUER & FELD
2022 · first_quarter · RR
Congressional and Administration outreach regarding use of Public Health Emergency authorities to address data submission requirements.
Congressional and Administration outreach regarding use of Public Health Emergency authorities to address data submission requirements.
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
General issues regarding access to cancer care and treatment.
Issues related to Medicare reimbursement for oncology care and alternative payment models; issues related to telehealth; issues related to COVID-19 testing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, U.S. Trade Representative (USTR), White House Office
SURGERY PARTNERS via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Legislation related to the Federal Trade Commission Contact Lens Rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Center for Medicare & Medicaid Innovation, HR 3 and other drug pricing proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL IMMIGRATION LAW CENTER via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Immigration reform provisions in the Build Back Better Act.
Filing targets: SENATE
MINOR LEAGUE BASEBALL RELIEF, INC via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Issues related to the Minor League Baseball COVID Relief Act, H.R. 4150 and S. 2233.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MICRON TECHNOLOGY, INC. via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Strategic and policy advice related to investment tax credits for semiconductors.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MCKESSON CORPORATION via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Issues related to COVID medical response,; COVID-19 vaccine distribution,; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act
Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748 - CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LABORATORY CORPORATION OF AMERICA HOLDINGS via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Nonhuman primate supply chain issues/China export ban.
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, U.S. Trade Representative (USTR), White House Office
CVS HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Strategic and policy advice related to general health care issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CENTRIENT PHARMACEUTICALS LLC via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Advocacy regarding solutions for onshoring supply chain and manufacturing of critical medicines back to the United States.
Advocacy regarding solutions for onshoring supply chain and manufacturing of critical medicines back to the United States.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE
AIR EVAC LIFETEAM via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Implementation of the No Surprises Act, as included in the Consolidated Appropriations Act, 2021 (P.L. 116-260); Build Back Better Act health care workforce provisions, Pathway to Health Careers and National Health Services Corps.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
ABBOTT LABORATORIES via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Strategic and policy advice related to health care issues, and COVID-19 legislation and regulations.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
1-800 CONTACTS via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · Q4
Legislation related to the Federal Trade Commission Contact Lens Rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL IMMIGRATION LAW CENTER via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · RA
Supporting immigration-related economic provisions in the FY22 budget reconciliation package.
MICRON TECHNOLOGY, INC. via AKIN GUMP STRAUSS HAUER & FELD
2021 · fourth_quarter · RR
Investment tax credits to promote domestic semiconductor manufacturing and issues related to corporate tax.
AIR EVAC LIFETEAM via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Implementation of the No Surprises Act, as included in the Consolidated Appropriations Act, 2021 (P.L. 116-260); eliminating the Provider Relief Fund Tax Penalties Act of 2021 (H.R. 2079).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
MINOR LEAGUE BASEBALL RELIEF, INC via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Issues related to the Minor League Baseball COVID Relief Act, H.R. 4150 and S. 2233.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MILLENNIUM HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Medicare and Medicaid coverage and reimbursement of laboratory tests; Data analytics to inform policy making; COVID-19 relief and response initiatives.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MCKESSON CORPORATION via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Issues related to COVID medical response; COVID-19 vaccine distribution; and health disparities; S.1362 - Pharmacy and Medically Underserved Areas Enhancement Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHATTERPROOF via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; H.R. 1384/S. 445 - Mainstreaming Addiction Treatment Act; H.R. 2067/S. 2235 - Medication Access and Training Expansion Act; Fiscal Year 2022 appropriations report language regarding substance use disorder treatment.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
LABORATORY CORPORATION OF AMERICA HOLDINGS via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Nonhuman primate supply chain issues/China export ban
Nonhuman primate supply chain issues/China export ban
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, U.S. Trade Representative (USTR), White House Office
STOPIT SOLUTIONS via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Issues related to implementation by the Department of Justice of the Stop School Violence Act grants.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
1-800 CONTACTS via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Legislation related to the Federal Trade Commission Contact Lens Rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TWENTY HOLDINGS INC via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
COVID-19 response; contact tracing; vaccines.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SIEMENS HEALTHINEERS (FKA VARIAN MEDICAL SYSTEMS, INC.) via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Issues related to radiation therapy reimbursement and alternative payment models; issues related to telehealth.; issues related to COVID-19 testing.
General issues regarding access to cancer care and treatment.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE, White House Office
CVS HEALTH via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Strategic and policy advice related to general health care issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CENTRIENT PHARMACEUTICALS LLC via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Advocacy regarding solutions for onshoring supply chain and manufacturing of critical medicines back to the United States.
Advocacy regarding solutions for onshoring supply chain and manufacturing of critical medicines back to the United States.
Advocacy regarding solutions for onshoring supply chain and manufacturing of critical medicines back to the United States.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Center for Medicare & Medicaid Innovation, H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act and other drug pricing proposals.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
GOJO INDUSTRIES via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Engagement around COVID-19 federal policy responses & national stockpile issues; Matters relating to USG vaccination efforts and return to in-person learning in K-12 schools. Matters relating to hand sanitizer safety; Fiscal year 2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Funding bill.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AON SERVICE CORPORATION via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Issues related to third party reinsurance.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ABBOTT LABORATORIES via AKIN GUMP STRAUSS HAUER & FELD
2021 · third_quarter · Q3
Strategic and policy advice related to health care and COVID-19 legislation and regulation.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
Pursue federal funding opportunities for air purification and disinfection systems.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Pursue federal funding opportunities for air purification and disinfection systems.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
Identify and pursue federal funding of new air purification and disinfection systems.
Artificial intelligence; electronic health record modernization; cybersecurity; FY23 National Defense Authorization Act